Category: 3. Business

  • AI needs power desperately. Here’s how to -2-

    AI needs power desperately. Here’s how to -2-

    The bull case: Aggregation networks will use the arbitrage window to build defensible positions, then graduate from tactical plays to structural alternatives.

    The bear case? Networks are temporary stop-gaps that will get crushed the moment the next wave of data centers begin operating.

    The honest assessment? These networks will gorge themselves during the feast years, then adapt to leaner times, remaining profitable, just not explosive.

    For investors, that means treating this as what it is: a defined-window arbitrage play with asymmetric upside if the shortage persists longer than expected, and manageable downside if you size positions appropriately and respect the exit timeline.

    The AI infrastructure buildout is real. The computing shortage is real. The 2027-’29 constraint window is real. The question is whether you’re positioned to profit from the temporary dislocation before the market normalizes.

    Read: AI has real problems. The smart money is investing in the companies solving them now.

    More: The AI boom is over – here’s your bubble survival guide

    -Jurica Dujmovic

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    12-06-25 1412ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • AI needs power desperately. Here’s how to invest in companies profiting from the pain.

    AI needs power desperately. Here’s how to invest in companies profiting from the pain.

    By Jurica Dujmovic

    The shortage is a lucrative opportunity – but the window is brief

    AI computing workloads could consume around 500 terawatt-hours annually by 2027 – about twice the U.K.’s total electricity consumption in 2023.

    Rising infrastructure costs and mounting capital constraints are deflating the AI boom. The hyperscalers can’t solve their computing problems fast enough, and that’s creating a rare arbitrage opportunity.

    The solution right now isn’t building data centers. The current investment opportunity lies in the temporary gap between exploding AI demand and the physical constraints of centralized infrastructure expansion. A handful of companies are exploiting this window – which likely will be a 24-to-36- month opportunity. For investors who understand the timing, it’s a compelling hedge against the AI infrastructure bottleneck.

    Physical barriers

    40% of AI data centers will face power constraints by 2027.

    AI’s limiting factor is no longer algorithms or data – it’s the brute-force physics of data-center expansion. Training large models demands tens of thousands of GPUs, dedicated networking and enormous power consumption. Gartner forecasts that 40% of AI data centers will face power constraints by 2027.

    The math is brutally simple: AI computing workloads could consume around 500 terawatt-hours annually by 2027 – about twice the U.K.’s total electricity consumption in 2023. This demand spike is already showing up in the grid.

    Dominion Energy (D), the biggest utility company in Virginia, nearly doubled its data-center power capacity under contract between July and December 2024, and the trend has persisted.

    Even with Microsoft (MSFT), Alphabet (GOOG) (GOOGL), Amazon.com (AMZN) and Meta Platforms (META) spending a combined $370 billion on capex in 2025, they can’t build fast enough. Construction and commissioning typically take 12 to 36 months, but when you include permitting and power-grid build-outs, a full data-center project can stretch to three to six years.

    Time and money

    The economics are compelling during this shortage window

    This time gap is the entire investment thesis.

    When essential resources become expensive and concentrated, parallel markets emerge. We saw this with electricity co-ops in the early 20th century, independent oil producers during OPEC’s reign and broadband resellers in the early internet era.

    With AI, the scarce resource is GPU computing. Several companies are building marketplaces that aggregate idle capacity – consumer GPUs, academic clusters, enterprise overstock – and resell it at a fraction of centralized data-center costs.

    The economics for these companies are compelling during this shortage window:

    Cost structure advantage: Alternative networks don’t finance data centers with debt. They pay participants directly for computing capacity through incentive structures, converting spare capacity into productive assets. The cost of scaling shifts from massive capex to distributed incentives.

    Speed to market: While hyperscalers wait 18 to 36 months for new facilities, these networks can add capacity node by node, with no billion-dollar commitments up front.

    Arbitrage pricing: These companies are capturing demand from the smaller labs, indie studios, emerging markets and others that are priced out of AWS GPU pricing but still need computing.

    The catch? The explosive growth window is finite. These networks will remain viable alternatives even after constraints ease – serving cost-sensitive workloads, emerging markets and indie developers – but the opportunity for substantial investment gains compresses as growth normalizes and hyperscalers’ capacity comes online.

    Read: AI data centers need juice. The next hot stocks give it.

    How to play the computing shortage

    Again, this isn’t a moonshot bet. It’s an infrastructure hedge with a defined window. Here are three approaches, ranked by risk profile:

    Render Network: Aggregates idle GPU capacity from individuals and studios, reselling to the highest bidder for rendering and AI workloads. Think of it as Airbnb for GPUs – idle capacity that would otherwise sit dormant gets monetized, and users get computing at a fraction of data-center pricing. Rather than operating expensive data centers, Render pays a fraction of that cost to harvest capacity from thousands of computers.

    io.net: Focuses on generic GPU computing for AI training and inference. The platform aggregates capacity from data centers, crypto miners and consumer hardware, creating a distributed alternative to centralized cloud providers. Its network is newer and more speculative than Render, but it’s capturing demand from AI startups that can’t afford or access hyperscaler GPU allocations.

    Akash Network: Takes the concept broader, offering a marketplace for general cloud computing and storage beyond just GPUs. This positions it as infrastructure for the full stack, not just AI-specific workloads. Akash is a privately held company but it does have a tradeable crypto token, AKT. This is the highest-risk play in this category, but offers the most diversified exposure if decentralized computing extends beyond AI.

    These are crypto token plays – not stocks

    Before going further, understand what you’re actually buying. All three of these networks operate through native cryptocurrency tokens, not traditional equity. There is no stock ticker, no brokerage-account access and no public-equity wrapper for these businesses.

    Direct exposure requires navigating cryptocurrency exchanges:

    — Render Network (RENDER) trades on Coinbase, Binance and Kraken.

    — is listed on select crypto exchanges such as Binance and Gate.io, with liquidity varying by venue and region.

    — Akash Network (AKT) trades on Coinbase, Kraken and similar venues.

    This means dealing with crypto custody – whether through exchange accounts or self-custody wallets – and accepting the regulatory uncertainty that comes with token investments. If you’re not comfortable with that infrastructure, this thesis won’t work for you.

    For investors who prefer traditional equity exposure, the closest alternatives are second-order beneficiaries of the same capacity constraint:

    — Data-center operators: Equinix EQIX, Digital Realty Trust DLR

    — Power infrastructure: Dominion Energy, Duke Energy DUK, NextEra Energy NEE

    — GPU supply chain: Nvidia NVDA, Broadcom AVGO, Super Micro Computer SMCI

    But here’s the critical distinction: These publicly traded companies benefit from the shortage itself – not from the temporary arbitrage window created by aggregating idle distributed capacity. They’ll do well regardless of whether decentralized computing succeeds. What they won’t give you is direct exposure to the specific dislocation that is going on now.

    Risk factors

    Let’s be clear about what could go wrong with this arbitrage strategy:

    Performance and reliability: Distributed GPU networks face inherent challenges with performance variance, latency and quality control. Enterprise customers paying for AI infrastructure demand reliability. If these networks can’t match centralized performance, the arbitrage doesn’t matter – customers won’t switch.

    Security and compliance: Regulated industries won’t run sensitive workloads on unknown hardware scattered globally. These networks are limited to specific use cases where data sovereignty and compliance aren’t blockers.

    Hyperscaler catch-up timeline: The base case assumes these constraints ease through 2027-’29 as new data centers and power infrastructure come online. If power constraints extend beyond 2029, the high-growth window for these companies stays open.

    Regulatory uncertainty: Several of these networks operate in regulatory gray areas. If governments decide to regulate decentralized computing infrastructure, costs increase and flexibility decreases.

    Crypto market contagion: These tokens trade on crypto exchanges and correlate with broader crypto markets. A bitcoin crash or crypto regulatory crackdown could affect these assets regardless of fundamentals.

    The investment timeline

    The window runs from early 2026 through 2027-’28, which is the core 24-to-36-month period. The broader infrastructure constraint lasts longer, but the outsized arbitrage compresses as hyperscalers come online. This aligns with the infrastructure constraint timeline I’ve been tracking, but extends beyond the initial shortage as power-grid limitations persist.

    Q1 2026: Begin building positions as the 2027 power constraint window becomes consensus view. Dollar-cost average to smooth volatility.

    Q2 2026-Q2 2027: Peak growth opportunity as AI demand continues accelerating while centralized capacity remains severely constrained. These networks capture maximum long-tail demand priced out of hyperscaler infrastructure.

    Q3 2027-Q2 2028: Growth continues, but begins normalizing as new data centers come online and power-grid upgrades progress. Monitor hyperscaler capacity announcements closely – each major facility completion incrementally compresses the arbitrage.

    Q3 2028-Q4 2029: Maturation phase. These networks settle into specialized roles – emerging markets, cost-sensitive workloads, indie developers. They remain viable businesses but growth normalizes.

    It is important to understand that this isn’t a binary “it works until it doesn’t” thesis. It’s a maturation curve where networks transition from high-growth arbitrage plays to steady-state infrastructure alternatives.

    The broader implication

    If GPU aggregation networks prove they can deliver reliable computing at competitive prices during the 2026-’28 constraint period, they will establish legitimacy. Even if hyperscalers eventually recapture market share, these networks will have carved out niches in emerging markets, indie studios and cost-sensitive workloads.

    (MORE TO FOLLOW) Dow Jones Newswires

    12-06-25 1412ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Assessing Aker BP (OB:AKRBP)’s Valuation After Its Strong One-Year Shareholder Return

    Assessing Aker BP (OB:AKRBP)’s Valuation After Its Strong One-Year Shareholder Return

    Aker BP (OB:AKRBP) has quietly outperformed the broader market over the past year, and with the share price hovering around NOK 253, investors are asking whether the current level still offers value.

    See our latest analysis for Aker BP.

    That recent 2.76% 7 day share price return, alongside an 8.67% year to date share price gain, sits on top of a robust 28.34% one year total shareholder return. This suggests momentum is still broadly building despite short term swings.

    If Aker BP’s run has you rethinking your energy exposure, this could also be a good moment to scan other resilient players across aerospace and defense stocks for fresh ideas.

    With solid earnings growth and the shares trading only slightly below analyst targets, the key question now is whether Aker BP is still undervalued on fundamentals or if the market is already pricing in future growth.

    Aker BP’s latest close of NOK 253.10 sits modestly below the narrative’s NOK 262 fair value, framing a small but notable upside grounded in execution.

    Aker BP aims to sustain production above 500,000 barrels per day beyond 2030, driven by their 2 billion barrel opportunity and projects like Yggdrasil and Johan Sverdrup. This supports long-term revenue growth through extended production capacities.

    Read the complete narrative.

    Curious how modest top line growth, rising margins and a reset earnings multiple still add up to upside from here? The narrative hides a surprisingly bold earnings trajectory, powered by disciplined volumes and a valuation reset that leans on future profitability rather than heroic growth. Want to see how those moving parts combine into that fair value call?

    Result: Fair Value of $262 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, structural risks, such as rising emissions costs and heavy reliance on key fields, could undermine margins and challenge the current fair value case.

    Find out about the key risks to this Aker BP narrative.

    On earnings, Aker BP looks far less forgiving, trading on an 18.8x price to earnings ratio versus a fair ratio of 11.2x; 11.7x for the wider European oil and gas group; and 9.2x for peers. That premium narrows the margin of safety, so how long can sentiment stay this strong?

    See what the numbers say about this price — find out in our valuation breakdown.

    OB:AKRBP PE Ratio as at Dec 2025

    If you would rather challenge these views or dig into the numbers yourself, you can build a personalised take in just minutes: Do it your way.

    A great starting point for your Aker BP research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

    Do not stop at a single stock when Simply Wall Street’s Screener can quickly surface fresh, data backed opportunities that others overlook and you can act on first.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AKRBP.OL.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Argan (AGX) Valuation Check After a Sharp Pullback in the Share Price

    Argan (AGX) Valuation Check After a Sharp Pullback in the Share Price

    Argan (AGX) has pulled back sharply this week, slipping about 12% in a single session and over 20% in the past week, even though the shares remain significantly higher over the past three months.

    See our latest analysis for Argan.

    Even after this week’s slide, Argan’s 1 year total shareholder return of around 115% and enormous 3 year total shareholder return appear to signal strong underlying momentum. At the same time, the recent pullback suggests investors are reassessing short term risk after a powerful run.

    If Argan’s surge has you rethinking your watchlist, it could be a smart moment to explore fast growing stocks with high insider ownership to research other fast moving opportunities with strong insider conviction.

    With Argan still trading below analyst targets and implying a hefty intrinsic discount, investors now face a pivotal question: Is the stock still undervalued, or is the market already pricing in years of future growth?

    With Argan closing around $313.70 versus a narrative fair value of roughly $295.75, the most followed view sees recent strength pushing into premium territory.

    Record backlog and continued project wins across gas, renewables, water treatment, and recycling plants provide multi-year revenue visibility, indicating potential for increased operating leverage and higher gross margins as larger projects are executed successfully.

    Read the complete narrative.

    Curious how multi year double digit expansion, moderating margins, and a richer future earnings multiple still add up to upside in this framework? The growth math behind that conclusion is not what most investors would expect from a construction contractor. Want to see which long term revenue and profit assumptions quietly justify paying up from here? Explore the full narrative to unpack the projections that support this valuation view.

    Result: Fair Value of $295.75 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, the thesis leans heavily on large gas projects, so any delays, cancellations, or faster than expected decarbonization could quickly pressure earnings.

    Find out about the key risks to this Argan narrative.

    Our SWS DCF model suggests Argan is trading about 42.7% below its fair value of $547.36, a sharp contrast to the narrative view that sees the stock as slightly overvalued. If cash flows point one way and sentiment another, which signal do you trust?

    Look into how the SWS DCF model arrives at its fair value.

    AGX Discounted Cash Flow as at Dec 2025

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Argan for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 906 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

    If you see the story differently or want to dig into the numbers yourself, you can build a custom view in minutes: Do it your way.

    A great starting point for your Argan research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Before the market’s next move leaves you catching up, put Simply Wall Street’s Screener to work and uncover focused opportunities that match your exact investing style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AGX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression

    Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression

    Zanubrutinib (Brukinsa) in combination with R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) displayed preliminary activity in patients with treatment-naive diffuse large B-cell lymphoma (DLBCL) with activation of the BCR signaling pathway and certain genetic mutations, according to data from a phase 2 study (NCT05290337) presented during the 2025 ASH Annual Meeting & Exposition.1

    Efficacy-evaluable patients who received the combination (n = 58) achieved an overall response rate (ORR) of 91.4%, including a complete response (CR) rate of 79.3%. The estimated 3-year progression-free survival (PFS) and overall survival (OS) rates were 80.3% (95% CI, 70.5%-91.5%) and 89.1% (95% CI, 81.2%-97.8%), respectively.

    Phase 2 Study of Zanubrutinib Plus R-CHOP in Untreated DLBCL With Specific Gene Expression: Key Takeaways

    • Efficacy-evaluable patients who received zanubrutinib plus R-CHOP (n = 58) achieved an ORR of 91.4%, with a CR rate of 79.3%.
    • The estimated 3-year PFS and OS rates were 80.3% (95% CI, 70.5%-91.5%) and 89.1% (95% CI, 81.2%-97.8%), respectively.
    • The most common any-grade AEs included infection (61.0%), leukopenia (54.2%), and neutropenia (52.5%).

    “Previous studies indicated that for those with specific gene mutations, R-CHOP demonstrated limited efficacy,” Qunling Zhang, MD, of the Department of Medical Oncology at Fudan University Shanghai Cancer Center in Shanghai, China, and colleagues noted in the presentation. “However, promising response rates with BTK inhibitors suggest the potential for combined therapeutic regimens within this patient cohort.”

    How was the phase 2 study designed?

    The phase 2 trial enrolled patients who were 18 to 75 years old with newly diagnosed DLBCL with activation of the BCR signaling pathway whose disease harbored a mutation in MYD88, CD79B, NOTCH1, or TP53, or carried a MYC gene translocation, at a single center in China.1,2 Other key eligibility criteria included an ECOG performance status of 0 to 1, a life expectancy of over 3 months, at least 1 measurable target lesion, a left ventricular ejection fraction of at least 50%, and normal hematological, hepatic and renal function.2

    Patients received 1 cycle of R-CHOP followed by 5 cycles of zanubrutinib in combination with R-CHOP.1The primary end point was the 3-year PFS rate. Secondary end points included ORR, event-free survival, OS, and safety.

    At baseline, the mean age in the overall population (n = 59) was 53.9 years (SD, 12.2). Most patients were male (62.7%), had disease that originated from non-Germinal center B-cell like cells (55.9%), and presented with stage III to IV disease (52.5%). The baseline IPI scores were 0 (30.5%), 1 (22.0%), 2 (22.0%), 3 (16.9%), and 4 (8.5%).

    Among the 58 patients who completed treatment and underwent tumor assessment, genetic alterations were found in MCD (42.4%), A53 (27.1%), BN2 (8.5%), MYC (rearrangement, 8.5%), N1 (5.1%), other (5.1%), and ST2 (3.4%).

    What were the subgroup and safety data?

    Additional findings from the phase 2 trial revealed that efficacy-evaluable patients with MCD mutations (n = 25) achieved a CR rate of 84%. The 3-year PFS rate was 96.0% (95% CI, 88.6%-100.0%) among these patients and the 3-year OS rate was 100%.

    Efficacy-evaluable patients with the A53/MYC/other subtype (n = 30) achieved a 3-year PFS rate of 71.6% (95% CI, 56.7%-90.5%). Patients with N1 disease (n = 3) had a 3-year PFS rate that was not reached; the 2-year PFS rate in this subgroup was 33.3%. The 2-year OS rates in the A53/MYC/other and N1 subgroups were 85.4% (95% CI, 73.0%-99.8%) and 33.3% (95% CI, 6.7%-100%), respectively.

    In terms of safety, any-grade adverse effects included infection (61.0%), leukopenia (54.2%), neutropenia (52.5%), alopecia (40.7%), thrombocytopenia (28.8%), anorexia or poor appetite (25.4%), nausea (20.3%), weight loss (16.9%), febrile neutropenia (15.3%), and elevated alanine aminotransferase levels (10.2%). Grade 3 to 4 AEs consisted of neutropenia (45.8%), leukopenia (42.4%), infection (27.1%), thrombocytopenia (20.3%), and febrile neutropenia (15.3%).

    Disclosures: Zhang listed no relevant financial relationships.

    References

    1. Zhang Q, Jiang S, Liu Y, et al. The phase II study of zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients with specific gene-expression. Blood. 2025;146(suppl 1):57. doi:10.1182/blood-2025-57
    2. ZR-CHOP in DLBCL with specific gene abnormality. ClinicalTrials.gov. Updated March 22, 2022. Accessed December 6, 2025. https://clinicaltrials.gov/study/NCT05290337

    Continue Reading

  • Super-resolution ultrasound quantifying microvascular alterations for early detection of metastatic cervical lymph nodes: a prospective diagnostic study

    To evaluate super-resolution ultrasound (SRUS) for characterizing microvascular morphology and hemodynamics in metastatic versus reactive cervical lymph nodes (LNs), with the aim of improving metastatic detection and reducing unnecessary biopsies. In this prospective study, 166 patients with histopathologically confirmed cervical LNs (77 metastatic, 89 reactive) underwent conventional ultrasound and contrast-enhanced SRUS (CE-SRUS) using a commercial US system and SonoVue® microbubbles. Quantitative SRUS parameters vascular density (VD), fractal dimension (FD), flow-weighted vascular density (FWVD), perfusion index (PI), velocity entropy (Vel Entropy), minimum velocity (Vmin) were extracted from whole-LN ROIs. Diagnostic performance was assessed via receiver operating characteristic (ROC) analysis and multivariate logistic regression. Metastatic LNs showed significantly higher VD (0.482 ± 0.073 vs. 0.405 ± 0.168, p < 0.001), FD (1.678 ± 0.070 vs. 1.626 ± 0.098, p < 0.001), FWVD (1.784 ± 0.592 vs. 1.495 ± 0.813, p = 0.013), PI (12.617 ± 2.563 vs. 10.369 ± 5.006, p < 0.001), and Vel Entropy (0.922 ± 0.092 vs. 0.796 ± 0.199, p < 0.001), but lower Vmin (2.572 ± 2.200 mm/s vs. 2.645 ± 2.800 mm/s, p = 0.017) compared to reactive LNs. Univariate ROC top performers included Dir Entropy (AUC = 0.723) and VD (AUC = 0.689). Multivariate analysis identified VD (OR = 1.046, p = 0.001), Vmin (OR = 0.525, p = 0.003), Velocity Variance (Vel Var) (OR = 1.973, p = 0.016), Vel Entropy (OR = 4.674, p = 0.042), and PI (OR = 2.481, p = 0.018) as independent predictors. The combined model achieved superior diagnostic performance (AUC = 0.813, 95% CI: 0.748–0.879; sensitivity = 76.6%, specificity = 79.8%; p < 0.001). SRUS enables non-invasive, high-resolution quantification of microvascular alterations in metastatic LNs. A multivariate model demonstrates excellent discriminative power, demonstrating significant potential to improve preoperative assessment and biopsy guidance in head and neck cancer.

    Continue Reading

  • Here Are My Top 3 Quantum Computing Stocks to Buy in December

    Here Are My Top 3 Quantum Computing Stocks to Buy in December

    • Microsoft and Alphabet have resources that quantum computing pure-plays could only dream about.

    • Nvidia has launched a device that allows for a hybrid quantum computing approach.

    • 10 stocks we like better than Alphabet ›

    Quantum computing has gone through two boom-and-bust hype cycles in under a year, but that doesn’t mean the technology is irrelevant. Instead, I think investors are focused on the wrong quantum computing stocks. While many have invested in quantum computing pure plays like Rigetti Computing and IonQ, some of the safer bets are in companies like Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), Microsoft (NASDAQ: MSFT), and Nvidia (NASDAQ: NVDA).

    All three of these larger companies have established cash flows that don’t make quantum computing supremacy as dire as it is for the pure-play companies. As a result, they can take more measured approaches to this innovative technology, and I think it makes them much better buys overall.

    Image source: Getty Images.

    The pure-play companies must disclose nearly every breakthrough or business win they achieve to attract investors. This makes them prone to hype cycles, which can eventually cause the stocks to crash once the market’s appetite for risk decreases.

    Alphabet and Microsoft aren’t subject to the same hype risk, as they only announce massive milestone achievements for their quantum computing technology. Alphabet’s most recent announcement regarding quantum computing was more than a month ago, when it announced running the first verifiable algorithm on its quantum computer. This is a big deal, as it shows that Alphabet can prove that its quantum computer is providing an advantage over traditional computing.

    Microsoft has also been relatively quiet on the quantum computing front, with its last major announcement being in February when it promoted its Majorana 1 custom quantum computing chip. Microsoft claims to have created a unique state of matter for controlling the particles in this quantum computing chip, and believes that this technology will allow Microsoft to easily scale and solve enterprise-level problems without the need to iterate on architecture. That could be a huge advantage, but it’s impossible to know where Microsoft stands with this technology, as it doesn’t update investors on every breakthrough.

    With the level of funding Alphabet’s and Microsoft’s quantum computing businesses have, they are both no-brainer picks in the industry. The pure-play companies will have a tough time competing against the sheer size and resources of these two, and I think that makes them top quantum computing stocks to buy right now.

    Continue Reading

  • China debuts new AI model for high-standard farmland protection

    China debuts new AI model for high-standard farmland protection

    A CAAS model shifts China’s farmland management from quantity preservation to quality-focused monitoring

    In a pilot program in Kunshan, east China’s Jiangsu Province, the model successfully created a closed-loop system by adjusting fertilization dynamically based on weather and crop growth cycles. PHOTO: PIXABAY

    China on Friday launched its first large artificial intelligence (AI) model dedicated to monitoring and protecting arable land, and it will serve as a new digital tool for the national strategy of storing grain in the land and in technology.

    Released by the Institute of Agricultural Resources and Regional Planning under the Chinese Academy of Agricultural Sciences (CAAS) on World Soil Day, the model aims to upgrade China’s farmland management from quantity-focused preservation to quality improvement — a task that traditional manual monitoring can no longer handle efficiently.

    Developed by a team led by Tang Huajun, an academician of the Chinese Academy of Engineering, the system integrates a central foundation model with dedicated “vertical models” designed for specific tasks such as field segmentation, crop classification and engineering quality inspection.

    Wu Wenbin, director general of the CAAS Institute of Agricultural Resources and Regional Planning, said that the AI model goes beyond passive observation. It can diagnose soil health, predict trends and autonomously generate management plans, offering full-life-cycle management for high-standard farmland.

    Nationwide, there are more than 66.7 million hectares of high-standard farmland, where soil fertility has been well-preserved with technological advancements and scientific farm management.

    In a pilot program in Kunshan, east China’s Jiangsu Province, the model successfully created a closed-loop system by adjusting fertilization dynamically based on weather and crop growth cycles.

    Industry experts have said the launch provides a technical driver for the sustainable management of agricultural resources, the improvement of arable land quality and the development of high-quality farmland in China.

    Continue Reading

  • Nvidia CEO says U.S. data centers take 3 years, but China ‘can build a hospital in a weekend’

    Nvidia CEO says U.S. data centers take 3 years, but China ‘can build a hospital in a weekend’

    Nvidia CEO Jensen Huang said China has an AI infrastructure advantage over the U.S., namely in construction and energy.

    While the U.S. retains an edge on AI chips, he warned China can build large projects at staggering speeds.

    “If you want to build a data center here in the United States from breaking ground to standing up a AI supercomputer is probably about three years,” Huang told Center for Strategic and International Studies President John Hamre in late November. “They can build a hospital in a weekend.”

    The speed at which China can build infrastructure is just one of his concerns. He also worries about the countries’ comparative energy capacity to support the AI boom.

    China has “twice as much energy as we have as a nation, and our economy is larger than theirs. Makes no sense to me,” Huang said.

    He added that China’s energy capacity continues to grow “straight up”, while the U.S.’s remains relatively flat.

    Still, Huang maintained that Nvidia is “generations ahead” of China on AI chip technology to support the demand for the tech and semiconductor manufacturing process.

    But he warned against complacency on this front, adding that “anybody who thinks China can’t manufacture is missing a big idea.”

    Yet Huang is hopeful about Nvidia’s future, noting President Donald Trump’s push to reshore manufacturing jobs and spur AI investments.

    ‘Insatiable AI demand’

    Early last month, Huang made headlines by predicting China would win the AI race—a message he amended soon thereafter, saying the country was “nanoseconds behind America” in the race in a statement shared to his company’s X account.

    Nvidia is just one of the big tech companies pouring billions of dollars into a data center buildout in the U.S., which experts tell Fortune could amount to over $100 billion in the next year alone.

    Raul Martynek, the CEO of DataBank, a company that contracts with tech giants to construct data centers, said the average cost of a data center is $10 million to $15 million per megawatt (MW), and a typical data centers on the smaller side requires 40 MW.

    “In the U.S., we think there will be 5 to 7 gigawatts brought online in the coming year to support this seemingly insatiable AI demand,” Martynek said.

    This shakes out to $50 billion on the low end, and $105 billion on the high end.

    Continue Reading

  • Apple Rocked by Executive Departures, With Chip Chief at Risk of Leaving Next – Bloomberg.com

    1. Apple Rocked by Executive Departures, With Chip Chief at Risk of Leaving Next  Bloomberg.com
    2. Apple Departures Point to Challenges for iPhone’s Dominance  The Wall Street Journal
    3. 7 Things To Know About Apple’s New General Counsel  Law360
    4. More than 10 top Apple executives have joined rivals in the past few months; What’s ‘behind’ the toughest talent ‘crisis’ iPhone maker is facing  Times of India
    5. New report sheds a bit more light on who at Apple has been departing for OpenAI  9to5Mac

    Continue Reading